L3VLUP
ProSign in

MDT · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MDTLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MDT
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterMDTLLY
Q3 202032 holders, $18.3bn33 holders, $14.1bn
Q4 202033 holders, $20.0bn29 holders, $17.3bn
Q1 202137 holders, $20.8bn24 holders, $23.0bn
Q2 202134 holders, $22.1bn24 holders, $27.8bn
Q3 202132 holders, $21.6bn31 holders, $29.9bn
Q4 202131 holders, $18.5bn31 holders, $34.7bn
Q1 202228 holders, $18.0bn24 holders, $35.3bn
Q2 202235 holders, $15.2bn33 holders, $42.7bn
Q3 202233 holders, $13.7bn31 holders, $43.4bn
Q4 202232 holders, $13.4bn31 holders, $46.6bn
Q1 202325 holders, $13.6bn33 holders, $44.3bn
Q2 202330 holders, $15.2bn37 holders, $59.6bn
Q3 202328 holders, $13.1bn44 holders, $67.6bn
Q4 202324 holders, $12.7bn45 holders, $73.6bn
Q1 202419 holders, $12.8bn41 holders, $95.3bn
Q2 202426 holders, $11.2bn43 holders, $110bn
Q3 202430 holders, $13.9bn45 holders, $107bn
Q4 202433 holders, $11.5bn46 holders, $93.9bn
Q1 202527 holders, $13.8bn42 holders, $98.4bn
Q2 202530 holders, $13.3bn43 holders, $93.2bn
Q3 202525 holders, $13.6bn39 holders, $86.7bn
Q4 202527 holders, $14.9bn41 holders, $123bn
Q1 202624 holders, $14.3bn39 holders, $106bn
Q2 202629 holders, $12.8bn44 holders, $132bn
MDT

Medtronic PLC

Holders
27
Reported value
$14.9bn
Buyers
24
Sellers
13

Breadth +11 among 92 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
41
Reported value
$123bn
Buyers
25
Sellers
22

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MDT (4)

Baillie Gifford & Co, First Eagle Investment Management LLC, MFS Investment Management, Two Sigma Investments LP

Only LLY (18)

Brevan Howard Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Man Group PLC, Marshall Wace LLP, Moore Capital Management LP, Point72 Asset Management LP, Quantbot Technologies LP, Renaissance Technologies LLC, Rokos Capital Management LLP, Soros Fund Management LLC, Steadfast Capital Management LP, Tudor Investment Corp

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →